Hemophilia A secondary prevention

Revision as of 14:33, 15 May 2017 by Tarek Nafee (talk | contribs)
Jump to navigation Jump to search

Hemophilia A Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hemophilia A from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hemophilia A secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hemophilia A secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hemophilia A secondary prevention

CDC on Hemophilia A secondary prevention

Hemophilia A secondary prevention in the news

Blogs on Hemophilia A secondary prevention

Directions to Hospitals Treating Hemophilia A

Risk calculators and risk factors for Hemophilia A secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Fahd Yunus, M.D. [2]

Overview

Secondary prevention for Hemophilia A is aimed at preventing spontaneous or excessive bleeds in patients who are high risk, and relies on the use of recombinant clotting factor VIII to prevent bleeding episodes.

Secondary Prevention

Secondary preventive measures to avoid Hemophilia A include the following:

  • Patients should be counseled on safe practices and routine accident prevention.
  • Patients with moderate-to-severe hemophilia may be managed with prophylactic transfusions of recombinant clotting factor VIII in order to prevent bleeding episodes.[1] The goal of prophylaxis is usually to keep clotting factor levels at 1 percent or greater at all times.[2]
  • Routine prophylactic transfusions are not recommended for patients with mild hemophilia.

References

  1. Franchini M, Mannucci PM (2012). "Past, present and future of hemophilia: a narrative review". Orphanet J Rare Dis. 7: 24. doi:10.1186/1750-1172-7-24. PMC 3502605. PMID 22551339.
  2. Prophylaxis: Administration and dosing schedules – World Federation of Hemophilia. Available at http://www.wfh.org/en/abd/prophylaxis/prophylaxis-administration-and-dosing-schedules. Accessed on Sept 20, 2016

Template:WH Template:WS